Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Doctors Hospital at Ohio Health
mi
from
Columbus, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Doctors Hospital at Ohio Health
mi
from
Columbus, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Grady Memorial Hospital
mi
from
Delaware, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Grady Memorial Hospital
mi
from
Delaware, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Fairfield Medical Center
mi
from
Lancaster, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Fairfield Medical Center
mi
from
Lancaster, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Strecker Cancer Center at Marietta Memorial Hospital
mi
from
Marietta, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Strecker Cancer Center at Marietta Memorial Hospital
mi
from
Marietta, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Licking Memorial Cancer Care Program at Licking Memorial Hospital
mi
from
Newark, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Licking Memorial Cancer Care Program at Licking Memorial Hospital
mi
from
Newark, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Mercy Medical Center
mi
from
Springfield, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Mercy Medical Center
mi
from
Springfield, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Community Hospital of Springfield and Clark County
mi
from
Springfield, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Community Hospital of Springfield and Clark County
mi
from
Springfield, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Mount Carmel St. Ann's Cancer Center
mi
from
Westerville, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Mount Carmel St. Ann's Cancer Center
mi
from
Westerville, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  11/23/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 11/23/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Stanford University
mi
from
Stanford, CA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Ohio State University
mi
from
Columbus, OH
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Vanderbilt University
mi
from
Nashville, TN
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance
mi
from
Seattle, WA
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Fred Hutchinson Cancer Research Center - Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated:  11/24/2015
Weill-Cornell Medical College
mi
from
New York, NY
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Enrolling
Updated: 11/24/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Status: Enrolling
Updated:  11/24/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Status: Enrolling
Updated: 11/24/2015
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies
Phase 1 Single Center, Randomized, Controlled Study Using Sublingual Immunotherapy for Timothy Grass and Dust Mite Allergies
Status: Enrolling
Updated:  11/24/2015
Stanford University
mi
from
Stanford, CA
Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies
Phase 1 Single Center, Randomized, Controlled Study Using Sublingual Immunotherapy for Timothy Grass and Dust Mite Allergies
Status: Enrolling
Updated: 11/24/2015
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Effects of Delayed Cord Clamping in Very Low Birth Weight Infants
Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants
Status: Enrolling
Updated:  11/27/2015
Women and Infants Hospital
mi
from
Providence, RI
Effects of Delayed Cord Clamping in Very Low Birth Weight Infants
Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants
Status: Enrolling
Updated: 11/27/2015
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis
Status: Enrolling
Updated:  11/30/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis
Status: Enrolling
Updated: 11/30/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis
Status: Enrolling
Updated:  11/30/2015
Intercoastal Medical Group
mi
from
Sarasota, FL
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis
Status: Enrolling
Updated: 11/30/2015
Intercoastal Medical Group
mi
from
Sarasota, FL
Click here to add this to my saved trials
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis
Status: Enrolling
Updated:  11/30/2015
University of California, San Diego
mi
from
San Diego, CA
Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization
An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis
Status: Enrolling
Updated: 11/30/2015
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Birmingham, AL
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Cullman, AL
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Tucson, AZ
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Phoenix, AR
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Phoenix, AR
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fullerton, CA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fullerton, CA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Long Beach, CA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Oceanside, CA
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Boulder, CO
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Colorado Springs, CO
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Denver, CO
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Englewood, CO
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Fort Collins, CO
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated:  11/30/2015
Clinical Research Facility
mi
from
Bradenton, FL
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Status: Enrolling
Updated: 11/30/2015
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials